Bone Health in Aging HIV Infected Women (NCT02815566) | Clinical Trial Compass
CompletedPhase 4
Bone Health in Aging HIV Infected Women
Canada34 participantsStarted 2017-09-12
Plain-language summary
Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for \> 6 months to : 1. Immediate switch of TDF/FTC to tenofovir alafenamide-emtricitabine (TAF/FTC) while continuing the third antiretroviral agent.; 2. Delayed switch; with switch of TDF/FTC to TAF/FTC at 48 weeks while continuing the third agent. Follow up of all subjects to 96 weeks.
Subject Population: The anticipated sample size is 128 HIV infected women aged 45-55 years (peri or early post menopause). .
Primary endpoint: Percentage change from baseline bone mineral density (BMD) at the lumbar spine at weeks 48 and 96.
Secondary Endpoints: BMD change at hip, trabecular bone score, estimated bone strength by high resolution peripheral quantitative computerized tomography (HR-pQCT), muscle quality, geriatric assessment; biomarkers of bone, immune activation and inflammation; HIV viral suppression; safety, lipid and renal function, cardiovascular risk scores at weeks 48 and 96.
Expected Outcomes: To determine if a switch from TDF/FTC to TAF?FTC improves BMD to a degree correlating with a decreased risk of fragility fracture in aging HIV infected women. Secondary outcomes will assess bone strength using new imaging modalities, timing of switch, and renal health. This data will be used by health policy makers and providers to determine the proper use of TAF/FTC in the aging HIV population.
Who can participate
Age range40 Years – 60 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Biological female aged 40-60
✓. Documented HIV-1 infection
✓. Peri-menopausal ( as documented by history).
✓. Signed Informed Consent Form and willing to comply with the protocol.
✓. Receiving a cART regimen containing a ritonavir boosted PI (darunavir, atazanavir, lopinavir,) or an NNRTI (efavirenz, nevirapine or rilpivirine) or an integrase inhibitor (dolutegravir or raltegravir or elvitegravir) in combination with TDF-FTC for \> 24 weeks.
✓. Stable viral suppression (plasma HIV-RNA\<50 copies/mL for \> 24 weeks). Single viral blip \<500/ml allowed if re-suppresses.
✓. If of childbearing potential, is using effective birth control methods and is willing to continue during the trial.
✓. Women will be assessed for vitamin D and calcium dietary intake; if inadequate for age, supplements will be recommended.
Exclusion criteria
✕
What they're measuring
1
Percent Change in Bone Mineral Density From Baseline at the Lumbar Spine